432 related articles for article (PubMed ID: 20592083)
21. Vif Proteins from Diverse Human Immunodeficiency Virus/Simian Immunodeficiency Virus Lineages Have Distinct Binding Sites in A3C.
Zhang Z; Gu Q; Jaguva Vasudevan AA; Jeyaraj M; Schmidt S; Zielonka J; Perković M; Heckel JO; Cichutek K; Häussinger D; Smits SHJ; Münk C
J Virol; 2016 Nov; 90(22):10193-10208. PubMed ID: 27581978
[TBL] [Abstract][Full Text] [Related]
22. Distinct determinants in HIV-1 Vif and human APOBEC3 proteins are required for the suppression of diverse host anti-viral proteins.
Zhang W; Chen G; Niewiadomska AM; Xu R; Yu XF
PLoS One; 2008; 3(12):e3963. PubMed ID: 19088851
[TBL] [Abstract][Full Text] [Related]
23. Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F.
Tian C; Yu X; Zhang W; Wang T; Xu R; Yu XF
J Virol; 2006 Mar; 80(6):3112-5. PubMed ID: 16501124
[TBL] [Abstract][Full Text] [Related]
24. APOBEC3G and APOBEC3F require an endogenous cofactor to block HIV-1 replication.
Han Y; Wang X; Dang Y; Zheng YH
PLoS Pathog; 2008 Jul; 4(7):e1000095. PubMed ID: 18604271
[TBL] [Abstract][Full Text] [Related]
25. Small-molecule inhibition of human immunodeficiency virus type 1 replication by targeting the interaction between Vif and ElonginC.
Zuo T; Liu D; Lv W; Wang X; Wang J; Lv M; Huang W; Wu J; Zhang H; Jin H; Zhang L; Kong W; Yu X
J Virol; 2012 May; 86(10):5497-507. PubMed ID: 22379088
[TBL] [Abstract][Full Text] [Related]
26. Structural Insights into HIV-1 Vif-APOBEC3F Interaction.
Nakashima M; Ode H; Kawamura T; Kitamura S; Naganawa Y; Awazu H; Tsuzuki S; Matsuoka K; Nemoto M; Hachiya A; Sugiura W; Yokomaku Y; Watanabe N; Iwatani Y
J Virol; 2016 Jan; 90(2):1034-47. PubMed ID: 26537685
[TBL] [Abstract][Full Text] [Related]
27. APOBEC3 degradation is the primary function of HIV-1 Vif determining virion infectivity in the myeloid cell line THP-1.
Ikeda T; Shimizu R; Nasser H; Carpenter MA; Cheng AZ; Brown WL; Sauter D; Harris RS
mBio; 2023 Aug; 14(4):e0078223. PubMed ID: 37555667
[TBL] [Abstract][Full Text] [Related]
28. Identification of dominant negative human immunodeficiency virus type 1 Vif mutants that interfere with the functional inactivation of APOBEC3G by virus-encoded Vif.
Walker RC; Khan MA; Kao S; Goila-Gaur R; Miyagi E; Strebel K
J Virol; 2010 May; 84(10):5201-11. PubMed ID: 20219919
[TBL] [Abstract][Full Text] [Related]
29. Identification of specific determinants of human APOBEC3F, APOBEC3C, and APOBEC3DE and African green monkey APOBEC3F that interact with HIV-1 Vif.
Smith JL; Pathak VK
J Virol; 2010 Dec; 84(24):12599-608. PubMed ID: 20943965
[TBL] [Abstract][Full Text] [Related]
30. Comparative analysis of the gene-inactivating potential of retroviral restriction factors APOBEC3F and APOBEC3G.
Bélanger K; Langlois MA
J Gen Virol; 2015 Sep; 96(9):2878-2887. PubMed ID: 26048885
[TBL] [Abstract][Full Text] [Related]
31. Identification of a Conserved Interface of Human Immunodeficiency Virus Type 1 and Feline Immunodeficiency Virus Vifs with Cullin 5.
Gu Q; Zhang Z; Gertzen CGW; Häussinger D; Gohlke H; Münk C
J Virol; 2018 Mar; 92(6):. PubMed ID: 29263270
[TBL] [Abstract][Full Text] [Related]
32. APOBEC3G is degraded by the proteasomal pathway in a Vif-dependent manner without being polyubiquitylated.
Dang Y; Siew LM; Zheng YH
J Biol Chem; 2008 May; 283(19):13124-31. PubMed ID: 18326044
[TBL] [Abstract][Full Text] [Related]
33. Identification of a novel HIV-1 inhibitor targeting Vif-dependent degradation of human APOBEC3G protein.
Pery E; Sheehy A; Nebane NM; Brazier AJ; Misra V; Rajendran KS; Buhrlage SJ; Mankowski MK; Rasmussen L; White EL; Ptak RG; Gabuzda D
J Biol Chem; 2015 Apr; 290(16):10504-17. PubMed ID: 25724652
[TBL] [Abstract][Full Text] [Related]
34. T-cell differentiation factor CBF-β regulates HIV-1 Vif-mediated evasion of host restriction.
Zhang W; Du J; Evans SL; Yu Y; Yu XF
Nature; 2011 Dec; 481(7381):376-9. PubMed ID: 22190036
[TBL] [Abstract][Full Text] [Related]
35. A single amino acid in human APOBEC3F alters susceptibility to HIV-1 Vif.
Albin JS; LaRue RS; Weaver JA; Brown WL; Shindo K; Harjes E; Matsuo H; Harris RS
J Biol Chem; 2010 Dec; 285(52):40785-92. PubMed ID: 20971849
[TBL] [Abstract][Full Text] [Related]
36. Endogenous origins of HIV-1 G-to-A hypermutation and restriction in the nonpermissive T cell line CEM2n.
Refsland EW; Hultquist JF; Harris RS
PLoS Pathog; 2012; 8(7):e1002800. PubMed ID: 22807680
[TBL] [Abstract][Full Text] [Related]
37. Conserved and non-conserved features of HIV-1 and SIVagm Vif mediated suppression of APOBEC3 cytidine deaminases.
Zhang W; Huang M; Wang T; Tan L; Tian C; Yu X; Kong W; Yu XF
Cell Microbiol; 2008 Aug; 10(8):1662-75. PubMed ID: 18419775
[TBL] [Abstract][Full Text] [Related]
38. HIV-1 and HIV-2 Vif interact with human APOBEC3 proteins using completely different determinants.
Smith JL; Izumi T; Borbet TC; Hagedorn AN; Pathak VK
J Virol; 2014 Sep; 88(17):9893-908. PubMed ID: 24942576
[TBL] [Abstract][Full Text] [Related]
39. Vif proteins from diverse primate lentiviral lineages use the same binding site in APOBEC3G.
Letko M; Silvestri G; Hahn BH; Bibollet-Ruche F; Gokcumen O; Simon V; Ooms M
J Virol; 2013 Nov; 87(21):11861-71. PubMed ID: 23986590
[TBL] [Abstract][Full Text] [Related]
40. Ubiquitination of APOBEC3G by an HIV-1 Vif-Cullin5-Elongin B-Elongin C complex is essential for Vif function.
Kobayashi M; Takaori-Kondo A; Miyauchi Y; Iwai K; Uchiyama T
J Biol Chem; 2005 May; 280(19):18573-8. PubMed ID: 15781449
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
